Fremanezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fremanezumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CALCA, CALCB
Clinical data
Trade names Ajovy
Synonyms TEV-48125
AHFS/Drugs.com Ajovy
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII

Fremanezumab (INN), marketed under the trade name Ajovy, is a humanized monoclonal antibody directed against calcitonin-related polypeptides (CGRP) alpha and beta.[1] It is used for the preventative treatment of migraine.

History[edit]

Fremanezumab was originated by Rinat Neuroscience Corporation, which licensed it to Teva.[2]

In 2018 Teva stopped development of fremanezumab for the treatment of chronic cluster headache after the primary endpoint of a Phase III trial was not met; Teva was still developing it for episodic cluster headache and migraine.[3]

The drug was approved by the US FDA for prevention of migraine in September 2018.[4]

See also[edit]

Other antibodies blocking the CGRP pathway:

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
  2. ^ "Fremanezumab - Teva Pharmaceutica". AdisInsight. Retrieved 19 June 2018.
  3. ^ "Teva Pulls Out of Chronic Cluster Headache Trial of Fremanezumab". MD Magazine. Retrieved 2018-06-19.
  4. ^ "Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults". Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Retrieved 7 October 2018.